Meeting
2017 ASCO Annual Meeting
A phase I study of enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with nivolumab in tumors of epithelial origin.
Authors
Wael A. Harb
Horizon Oncology Center, Lafayette, IN
Wael A. Harb , Lee S. Rosen , Ding Wang , Marwan Fakih , Daruka Mahadevan , Wendy Clemens , Giovanni Selvaggi , Suzanne Bosque , Richard Brown , Simon Alvis , Brian Champion , Hilary McElwaine-Johnn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02636036
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3115)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3115
Abstract #
TPS3115
Poster Bd #
198a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
First Author: Nicolas Villanueva
First Author: Igor Tsaur
Poster
2024 ASCO Annual Meeting
Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.
First Author: Xiangdong Cheng
Poster
2023 ASCO Annual Meeting
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
First Author: Colette Shen